Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H
- 1 June 1990
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 33 (6), 1729-1735
- https://doi.org/10.1021/jm00168a030
Abstract
D-Phe-Arg-H sulfate (GYKI-14166) is a highly active and selective inhibitor of thrombin both in vitro and in vivo. Recent studies on the stability of D-Phe-Arg-H in neutral aqueous solution at higher temperature have revealed that it is transformed into inactive 5,6,8,9,10,10a-hexahydro-2-(3''-guanidinopropyl)-5-benzyl-6-oxoimidazo[1,2-a]pyrrolo[2,1-c]pyrazine. No such inactivation could be observed with Boc-D-Phe-Pro-Arg-H (GYKI-14451), but this compound was far less specific than the free peptide as it inhibited thrombin and, for instance, plasmin equally well. Assuming that the transformation of free tripeptide aldehyde, mentioned above, can only be initiated by a primary amino terminus, the N-alkyl derivatives of D-Phe-Pro-Arg-H were prepared. Of the new analogues, D-MePhe-Pro-Arg-H (GYKI-14766) proved to be as highly active and selective anticoagulant as its parent compound and was not inactivated by transformation into a heterocyclic compound.This publication has 6 references indexed in Scilit:
- Tritiated peptides. 12. Synthesis and biological activity of [4-3H-Phe8]substance PJournal of Medicinal Chemistry, 1982
- FIBRIN, RED CELL AND PLATELET INTERACTIONS IN AN EXPERIMENTAL MODEL OF THROMBOSISBritish Journal of Pharmacology, 1982
- D-PHE-PRO-ARGCH2Cl-A selective affinity label for thrombinThrombosis Research, 1979
- Synthetic peptide derivatives that bind to fibrinogen and prevent the polymerization of fibrin monomersProceedings of the National Academy of Sciences, 1978
- Platelet Counts with the Coulter CounterAmerican Journal of Clinical Pathology, 1965
- The Partial Thromboplastin Time with Kaolin: A Simple Screening Test for First Stage Plasma Clotting Factor DeficienciesAmerican Journal of Clinical Pathology, 1961